Aarey Drugs & Pharmaceuticals Ltd
Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) last reported results for the quarter ended Jun 2026, with sales of ₹44.63 crore and net profit of ₹1.02 crore. The stock last traded at ₹103, a market capitalisation of ₹329 crore, on a P/E of 78.8. Over the past 52 weeks the stock has ranged between ₹50.3 and ₹108. Figures are as of 6 Oct 2026 and are not real time.
Aarey Drugs & Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹103
- Market cap
- ₹329 cr
- Stock P/E
- 78.8
- Book value
- ₹53
- ROE
- 2.75%
- ROCE
- 5.58%
- Dividend yield
- 0.00%
- 52w high / low
- 108/50.3
Metrics as of 6 Oct 2026. Not real time.
Track Aarey Drugs & Pharmaceuticals Ltd
Cruxal reads every Aarey Drugs & Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Aarey Drugs & Pharmaceuticals Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 6%
- 3 Years
- 4%
- TTM
- -8%
- 10 Years
- 12%
- 5 Years
- -9%
- 3 Years
- 2%
- TTM
- 0%
- 10 Years
- 8%
- 5 Years
- 23%
- 3 Years
- 32%
- 1 Year
- 24%
- 10 Years
- 5%
- 5 Years
- 4%
- 3 Years
- 3%
- Last Year
- 3%
Aarey Drugs & Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹44.63 cr, down 56.3% from ₹102 cr a year earlier. Net profit was ₹1.02 cr, down 25.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 105 | 134 | 108 | 102 | 84.16 | 96.43 | 189 | 44.63 |
| Expenses | 101 | 132 | 112 | 101 | 81.52 | 97.94 | 185 | 43.31 |
| Operating profit | 3.72 | 2.2 | -4.21 | 1.71 | 2.64 | -1.51 | 4.34 | 1.32 |
| OPM % | 3.54% | 1.64% | -3.89% | 1.67% | 3.14% | -1.57% | 2.29% | 2.96% |
| Other income | 0.02 | 0.68 | 7.54 | 1.55 | 0.79 | 4.18 | -0.43 | 1.72 |
| Interest | 0.49 | 0.58 | 1.3 | 1.04 | 1.26 | 0.92 | 1.78 | 1.67 |
| Depreciation | 1.51 | 0.9 | 0.41 | 0.49 | 0.69 | 0.83 | 0.85 | 0.85 |
| Profit before tax | 1.74 | 1.4 | 1.62 | 1.73 | 1.48 | 0.92 | 1.28 | 0.52 |
| Tax % | 8.62% | 48.57% | 71.60% | 20.81% | 31.08% | 38.04% | -21.88% | -98.08% |
| Net profit | 1.6 | 0.72 | 0.47 | 1.37 | 1.02 | 0.57 | 1.56 | 1.02 |
| EPS (₹) | 0.57 | 0.25 | 0.17 | 0.48 | 0.36 | 0.20 | 0.55 | 0.36 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Aarey Drugs & Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 396 | 349 | 354 | 298 | 348 | 493 | 419 | 396 | 474 | 472 | 415 |
| Operating profit | 10 | 8 | 8 | 3 | 5 | 11 | 8 | 4 | 3 | 7 | 7 |
| OPM % | 2.4% | 2.2% | 2.2% | 1.1% | 1.3% | 2.3% | 1.8% | 1.1% | 0.6% | 1.5% | 1.6% |
| Net profit | 5 | 6 | 7 | 6 | 7 | 7 | 4 | 5 | 4 | 4 | 4 |
| EPS (₹) | 3.02 | 2.64 | 2.80 | 2.48 | 2.78 | 2.58 | 1.49 | 1.67 | 1.42 | 1.40 | 1.47 |
TTM is the trailing twelve months to the most recent quarter.
Aarey Drugs & Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 18 | 23 | 23 | 23 | 23 | 25 | 25 | 28 | 28 | 28 |
| Reserves | 31 | 57 | 63 | 69 | 75 | 88 | 92 | 105 | 110 | 122 |
| Borrowings | 10 | 3 | 16 | 18 | 18 | 14 | 38 | 31 | 35 | 50 |
| Other liabilities | 83 | 86 | 43 | 84 | 116 | 117 | 136 | 139 | 117 | 97 |
| Total liabilities | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 | 297 |
| Fixed assets | 12 | 12 | 12 | 12 | 14 | 14 | 14 | 13 | 16 | 26 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 |
| Other assets | 130 | 157 | 133 | 181 | 218 | 230 | 277 | 289 | 272 | 269 |
| Total assets | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 | 297 |
As reported by the company. Total assets equal total liabilities by construction.
Aarey Drugs & Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | -20 | 1 | 3 | 5 | 0 | -1 | -3 | 10 | 10 |
| Cash from investing | -5 | -1 | -1 | -1 | -3 | -3 | 0 | -2 | -6 | -12 |
| Cash from financing | 4 | 23 | -2 | -2 | -2 | 2 | 1 | 6 | -4 | 2 |
| Net cash flow | -1 | 2 | -3 | 0 | 0 | -0 | 1 | 1 | -0 | -0 |
| Free cash flow | -4 | -21 | -1 | 2 | 3 | -2 | -2 | -4 | 5 | -2 |
| CFO / operating profit | 28% | -232% | 37% | 135% | 154% | 36% | 13% | -37% | 421% | 164% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Aarey Drugs & Pharmaceuticals Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 22% | 14% | 12% | 8% | 9% | 10% | 6% | 6% | 6% | 6% |
| Debtor days | 75 | 100 | 109 | 118 | 170 | 101 | 165 | 170 | 103 | 100 |
| Inventory days | 5 | 16 | 23 | 21 | 20 | 11 | 26 | 33 | 36 | 33 |
| Days payable | 71 | 84 | 40 | 98 | 120 | 86 | 115 | 123 | 81 | 66 |
| Cash conversion cycle | 9 | 32 | 92 | 42 | 69 | 26 | 76 | 80 | 58 | 68 |
| Working capital days | 34 | 69 | 77 | 99 | 91 | 68 | 89 | 106 | 89 | 90 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Aarey Drugs & Pharmaceuticals Ltd shareholding pattern
Promoters held 42.79% at Aug 2026, down from 44.80% at Sep 2025. FIIs 4.41% and DIIs 1.49%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 44.80% | 44.80% | 44.80% | 44.80% | 39.05% | 37.71% | 37.71% | 42.79% |
| FIIs | 2.34% | 2.34% | 1.97% | 1.13% | 3.86% | 4.18% | 4.81% | 4.41% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.62% | 1.62% | 1.49% |
| Public | 52.86% | 52.86% | 53.23% | 54.07% | 57.09% | 56.49% | 55.87% | 51.31% |
| No. of shareholders | 16,288 | 16,257 | 15,796 | 14,897 | 14,063 | 14,188 | 13,478 | 13,480 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Aarey Drugs & Pharmaceuticals Ltd corporate filings
- Compliance Certificate Under Reg 74(5) of SEBI(DP) Regulation 2018Company Updatelow impact
- Corporate Action: Conversion of Warrants into Equity Shares with Significant Capital InfusionCompany Updatehigh impact
Cruxal's analysis: Aarey Drugs and Pharmaceuticals Limited announced the allotment of 11.5 lakh equity…
Read the full analysis - Aarey Drugs & Pharmaceuticals Limited Receives Shareholder Approval for Related Party Transactions with Over 99.99% Voting SupportAGM/EGMmedium impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Limited, a small-cap company with a market cap of…
Read the full analysis - Promoter Share Allotment Significantly Alters Ownership Structure of Aarey Drugs & Pharmaceuticals LtdInsider Trading / SASThigh impact
Cruxal's analysis: Nimit Rajesh Ghatalia and promoter group have completed a substantial allotment of shares…
Read the full analysis - SEBI Filing Reveals Acquisition of 15 Lakh Shares by Nimit Rajesh Ghatalia in Aarey Drugs & Pharmaceuticals Ltd at ~INR 10/- per shareInsider Trading / SASThigh impact
Cruxal's analysis: Nimit Rajesh Ghatalia has disclosed acquiring 1.5 lakh equity shares of Aarey Drugs &…
Read the full analysis - Aarey Drugs & Pharmaceuticals discloses regulatory filing under SEBI SAST Reg 29(1) on October 3, 2026Otherslow impact
Cruxal's analysis: The company, a small-cap with a market cap of approximately 281.87 crore, filed a…
Read the full analysis - SEBI SAST Regulation Disclosure by Aarey Drugs & Pharmaceuticals LtdOtherslow impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Ltd filed a disclosure under SEBI SAST Regulation 29(2) on…
Read the full analysis - Aarey Drugs & Pharmaceuticals discloses regulatory compliance under SEBI PIT Reg. 2015Otherslow impact
Cruxal's analysis: The company, with a market cap of approximately 281.87 crore, has filed a disclosure…
Read the full analysis - Aarey Drugs & Pharmaceuticals Limited holds AGM; no new financial disclosures or strategic updates providedAGM/EGMlow impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Limited conducted its 36th AGM on 30th September 2026…
Read the full analysis - Aarey Drugs & Pharmaceuticals Ltd. announces conversion of warrants into equity shares, issuing 11.5 lakh new shares at a premium, leading to a ~4.07% increase in paid-up capitalOthershigh impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Ltd. has approved the allotment of 11,50,000 equity shares…
Read the full analysis - Intimation for Closure of trading WindowInsider Trading / SASTlow impact
- Aarey Drugs & Pharmaceuticals Ltd: Routine Regulatory Disclosure Under SEBI Regulation 30Company Updatelow impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Ltd has filed a routine disclosure under Regulation 30 of…
Read the full analysis - Aarey Drugs & Pharmaceuticals Ltd publishes mandatory newspaper notice for regulatory complianceCompany Updatelow impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Ltd has fulfilled a routine regulatory requirement under…
Read the full analysis - Aarey Drugs & Pharmaceuticals Ltd announces 36th Annual General Meeting and Integrated Annual ReportOtherslow impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Ltd has filed its notice and Integrated Annual Report for…
Read the full analysis - Aarey Drugs & Pharmaceuticals Ltd. Announces 36th AGM and Related Party Transaction ApprovalsAGM/EGMmedium impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Ltd. has scheduled its 36th Annual General Meeting for…
Read the full analysis - Aarey Drugs & Pharmaceuticals Ltd announces book closure for upcoming AGMCorp. Actionlow impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Ltd has issued an intimation regarding the closure of its…
Read the full analysis - Aarey Drugs & Pharmaceuticals Ltd. schedules 36th Annual General Meeting for September 30, 2026Otherslow impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Ltd. has announced the scheduling of its 36th Annual…
Read the full analysis - Aarey Drugs & Pharmaceuticals Ltd publishes mandatory newspaper notice under Regulation 30Company Updatelow impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Ltd has fulfilled its regulatory obligation under SEBI…
Read the full analysis - Aarey Drugs & Pharmaceuticals reports significant revenue contraction and margin pressure for Q1 FY2027Board Meetinghigh impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Limited reported a sharp decline in financial performance…
Read the full analysis - Aarey Drugs & Pharmaceuticals Ltd. schedules Board Meeting for June 2026 quarterly resultsBoard Meetinglow impact
Cruxal's analysis: Aarey Drugs & Pharmaceuticals Ltd. has formally intimated the stock exchanges regarding a…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.